The antimicrobial hygromycin A was shown to clear Lyme disease in mice, representing a promising therapeutic against the disease.
List view / Grid view
New dendritic hydrogels were tested against several infectious bacteria and could be used as an an antibiotic-free treatment in the future.
The metagenomic method, termed SMAGLinker, could improve the accuracy and resolution of microbial characterisation to improve medicine design.
A new ex vivo model treated animal wounds with mesenchymal stromal cells (MSCs) and reduced MRSA infection, expanding therapeutic options for humans.
The Gut Cell Atlas comprises 428,000 cells in the gut and sheds light on the origin of Crohn’s disease and other intestinal diseases.
Researchers have revealed that the protein APOL3 acts as a detergent in human cells, potentially leading to new antibacterial treatments.
A research team have created a new strategy for developing an effective vaccine against a widespread form of tuberculosis.
Researchers have developed a new method that could make enzyme replacement therapy more efficient for Pompe disease treatment.
Researchers have used fruit fly larvae to explore how alpha-synuclein impacts the mitochondria, advancing the study of Parkinson’s disease.
Scientists have used genetic sequencing to demonstrate how the transmission of gut bacteria influences its evolution and functions, which could effect human health.
Researchers have been using artificial intelligence to study how the microbiome interacts with the human system to improve vaccine response.
Eran Blacher has won the NOSTER & Science Microbiome Prize for discovering the link between the microbiome and neurodegenerative diseases.
Researchers have used comparative metabologenomics to uncover what may be “silencing” bacteria to produce desirable compounds.
Acetate was found to be involved in regulating complex microbes and could help trigger an immune response against harmful bacteria in mice.
Researchers have screened bacteria in the gut, finding that Bifidobacteria have inhibitory activity against SARS-CoV-2.